Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.

Zhitao YingHaiyan YangYe GuoWenyu LiDehui ZouDao-Bin ZhouZhao WangMingzhi ZhangJianqiu WuHui LiuPian ZhangSu YangZisong ZhouHongxia ZhengYuqin SongJun Zhu

Published in: Cancer medicine (2020)

Relma-cel met the primary endpoint analysis and demonstrated a high rate of durable responses and low rate of CAR-T-associated toxicities in patients with r/r LBCL in a multicenter trial supporting regulatory submission in China.

Keyphrases

diffuse large b cell lymphoma
acute lymphoblastic leukemia
acute myeloid leukemia
clinical trial
study protocol
transcription factor
multiple myeloma
randomized controlled trial
phase iii
tyrosine kinase
phase ii
hodgkin lymphoma
double blind
data analysis